Health and convinience segment contributes 3% revenue.However, it has very high potential for future growth. If these products are clicked in future, lt foods will definately become FMCG company.
Disc…invested
Health and convinience segment contributes 3% revenue.However, it has very high potential for future growth. If these products are clicked in future, lt foods will definately become FMCG company.
Disc…invested
Now for the quarter, we delivered 9% revenue growth in the course from operations
Slowdown in the U.S. biotech funding did impact Discovery Services
We expect a little bit slower growth coming out of the U.S. biotech segment for 1, 2, maybe 3
more quarters before it annualizes out
Can you share the reason to add this?
What is the percentage of allocation in your portfolio?
Any update on KPIT guidance in Q3FY24? is there any change?
Yes, got your point about a marginal difference between 195 and CMP. However, that difference can be substantial for those who have a larger holding (and hence large RE qty), and also once CMP moves north. And also if someone made their first entry above 195 and has an avg above 200.
My view is that CMP will remain low until Mondays cutoff. Subscription should be huge as Skipper is poised for exponential growth.
Can you shed some light on how you’ve applied, what steps you’ve followed? Will help those of us who are first time pref appliers and new to the process.
I checked via my bank dashboard and I can see the option but the price is 48 and not 195, which I’m assuming will change post Monday?
For any breakup you could find for this product-wise, please mention the source and if in ar or specific concall then page if you have it will be helpful.
Right now I can’t find any resources where they mention their sales breakup in insecticides, fungicides, and herbicides but BCIL’s main products include Chlorpyrifos, Pymetrozine, Azoxystrobin, and Fipronil. The top three products of the company, Chlorpyrifos, Azoxystrobin, and Fipronil, formed around 82% of the company’s revenues in FY23
Apcotex(dec 2023, investor presentation)
• Quarterly volume growth of 21% YoY, 8% volume drop QoQ mainly due to NBR & HSR
• Highest Quarterly export volume growth of 98% YoY led by Nitrile Latex, Carpet and Construction
• Revenue growth of 10%, due to increased volumes in spite of challenging market conditions
• EBITDA: decreased 17% YoY due to lower margins in NBR, XNB and Paper, and there was no significant inventory loss/gain
in this quarter
• PBT and PAT lower YoY, because of increase in Depreciation and Interest Cost due to new expansion projects.
Disc…invested
The company mentioned it would call for it. Not sure how it happens. My guess is after you are sure of the number allotted to you , you can make the rest of the payment. I have already made my application.
If you make mistake in ASBA or miss the dead line I’m afraid I don’t think you can make amends.
maybe someone knowledgeable can pitch in.
EvoLve theme by Theme4Press • Powered by WordPress & Rakesh Jhunjhunwala Latest Stock Market News
The Most Valuable Commodity Is Information!